Cargando…

The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD

The prognosis of nonalcoholic fatty liver disease (NAFLD) patients depends on liver-related events (LREs), extrahepatic cancers, and major adverse cardiovascular events (MACEs). The fibrosis-4 (FIB-4) index is one of the most reliable and useful predictors of the degree of liver fibrosis. Recent stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamada, Yoshihiro, Munekage, Kensuke, Nakahara, Takashi, Fujii, Hideki, Sawai, Yoshiyuki, Doi, Yoshinori, Hyogo, Hideyuki, Sumida, Yoshio, Imai, Yasuharu, Miyoshi, Eiji, Ono, Masafumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9824239/ https://www.ncbi.nlm.nih.gov/pubmed/36615725 http://dx.doi.org/10.3390/nu15010066

Ejemplares similares

Serum Mac‐2 binding protein level predicts the development of liver‐related events and colorectal cancer in patients with NAFLD
por: Kamada, Yoshihiro, et al.
Publicado: (2022)

FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic
por: Sumida, Yoshio, et al.
Publicado: (2021)

Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
por: Sumida, Yoshio, et al.
Publicado: (2012)

A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD
por: Kawaguchi, Takumi, et al.
Publicado: (2018)

Characterization of Nutrient Intake in Biopsy-Confirmed NAFLD Patients
por: Kamada, Yoshihiro, et al.
Publicado: (2022)

Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
por: Kamada, Yoshihiro, et al.
Publicado: (2017)

Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes
por: Ishiba, Hiroshi, et al.
Publicado: (2020)

Evaluation of postprandial hypoglycemia in patients with nonalcoholic fatty liver disease by oral glucose tolerance testing and continuous glucose monitoring
por: Oki, Yusuke, et al.
Publicado: (2018)

Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis
por: Kamada, Yoshihiro, et al.
Publicado: (2013)

Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS
por: Ochi, Tsunehiro, et al.
Publicado: (2017)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Colognesi, Martina, et al.
Publicado: (2020)

Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review
por: Lee, Jenny, et al.
Publicado: (2021)

A Systematic Review of NAFLD-Associated Extrahepatic Disorders in Youths
por: Pacifico, Lucia, et al.
Publicado: (2019)

Eradication of hepatitis C virus with direct‐acting antivirals improves glycemic control in diabetes: A multicenter study
por: Takahashi, Hirokazu, et al.
Publicado: (2020)

Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4
por: John, Katharina, et al.
Publicado: (2022)

FIB‑4 index and NAFLD fibrosis score are useful indicators for screening high‑risk groups of non‑viral hepatocellular carcinoma
por: Imai, Kenji, et al.
Publicado: (2023)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations
por: Adinolfi, Luigi Elio, et al.
Publicado: (2016)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease
por: Takahashi, Hirokazu, et al.
Publicado: (2023)

Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study
por: Björkström, Karl, et al.
Publicado: (2022)

Modification of a simple clinical scoring system as a diagnostic screening tool for non‐alcoholic steatohepatitis in Japanese patients with non‐alcoholic fatty liver disease
por: Nakamura, Akinobu, et al.
Publicado: (2013)

SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum
por: Kamada, Yoshihiro, et al.
Publicado: (2022)

FIB nanostructures
por: Wang, Zhiming M
Publicado: (2013)

Glycemic Variability Is an Independent Predictive Factor for Development of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
por: Hashiba, Motoi, et al.
Publicado: (2013)

Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care
por: Davyduke, Tracy, et al.
Publicado: (2019)

FIB-4 is closer to FibroScan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning
por: Ding, Yuping, et al.
Publicado: (2023)

Role of Oxidative Stress in Hepatic and Extrahepatic Dysfunctions during Nonalcoholic Fatty Liver Disease (NAFLD)
por: Gonzalez, Andrea, et al.
Publicado: (2020)

The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC)
por: Venniyoor, Ajit, et al.
Publicado: (2021)

Comparing Xe(+)pFIB and Ga(+)FIB for TEM sample preparation of Al alloys: Minimising FIB‐induced artefacts
por: Zhong, Xiangli, et al.
Publicado: (2020)

Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population
por: Kolhe, Kailash Marotrao, et al.
Publicado: (2019)

Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients
por: Lima, Rodrigo Vieira Costa, et al.
Publicado: (2021)

Sequential Combination of FIB-4 Followed by M2BPGi Enhanced Diagnostic Performance for Advanced Hepatic Fibrosis in an Average Risk Population
por: Kim, Mimi, et al.
Publicado: (2020)

FIB the fractured femur
por: Shahzad, H, et al.
Publicado: (2013)

Clinical Profiles of Asians with NAFLD: A Systematic Review and Meta-Analysis
por: Kam, Leslie Y., et al.
Publicado: (2022)

FibH Gene Complete Sequences (FibHome) Revealed Silkworm Pedigree
por: Lu, Wei, et al.
Publicado: (2023)

Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease
por: Unsal, İlknur Ozturk, et al.
Publicado: (2022)

Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist?
por: Nones, Rodrigo Bremer, et al.
Publicado: (2017)

T tube drainage for spontaneous perforation of the extrahepatic bile duct
por: Mizutani, Satoshi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kgld45otb3uk94usnk8bu6heeq